OncoMatch/Clinical Trials/NCT03523975

Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma

Is NCT03523975 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including Venetoclax and Lenalidomide for mantle cell lymphoma.

Phase 1/2RecruitingCity of Hope Medical CenterNCT03523975Data as of May 2026

Treatment: Venetoclax · Lenalidomide · Rituximab — The purpose of this study is to determine if giving an experimental drug called venetoclax in combination with lenalidomide and rituximab is safe and effective for treating people with Mantle Cell Lymphoma (MCL).

Check if I qualify

Extracted eligibility criteria

Cancer type

Non-Hodgkin Lymphoma

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Prior therapy

No prior treatment (treatment-naive required)

Max 0 prior lines

Cannot have received: chemotherapy

Lab requirements

Blood counts

Adequate organ function

Kidney function

Adequate organ function

Liver function

Adequate organ function

Adequate organ function

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

City of Hope Medical center · Duarte, California
University of Michigan · Ann Arbor, Michigan
The Ohio State University Comprehensive Cancer Center · Columbus, Ohio

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify